PrimeGene

Founded in 2016 and based in Beijing, China, PrimeGene operates as a biopharmeceutical company that focuses on the innovative drug developer that specializes in the research and development of immuno-inflammatory disease drugs and related products. It acquired 7 clinical approvals in 2023. The company acquired certifications such as quality management system and Zhongguancun High-tech Enterprise, etc. Yunlong Du, the CEO of the company, graduated from Albany Medical College in the United States, and worked in Pfizer, GSK and other pharmaceutical companies for more than 20 years.

In 2022, the company was listed on the New Third Board. In May 2024, PrimeGene raised a strategic investment for CNY 100 million. In January 2025, PrimeGene raised more than CNY 300 million in series B funding from new investors Zhengqi Financial Holdings Corporation, Tech-Intelligence Capital, Beijing Capital Technology Development Group, Shunlong Private Equity Bond Investment, and E-Town International Industrial Investment, with individual and other investors. PrimeGene mainly engages in the research and development and industrialization of innovative immune-inflammatory drugs.

Its product pipelines can be categorized into 4 series, which are dermatology, ophthalmology, rhinology and respiratory system. The dermatology products include PG- 019, PG-033, etc. The company adopts technologies such as computer-aided drug design, first-to-compound optimization, target analysis and precision screening. Products can be used in the treatment of atopic dermatitis, chronic itchy rash, glaucoma and other diseases.

The company generates revenue by selling immune-inflammatory drugs. The company will use the funds for researching Atopic Dematitis AD, claiming NDA, and expanding application and innovation of PG-011.